Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370524 · ClinicalTrials.gov registry record · Phase 1
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
A Phase 1 study, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02370524 is a Phase 1 study that has completed, run by Molecular NeuroImaging. The registered enrollment target is 16 participants.
The verdict
NCT02370524, a Phase 1 study, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The primary objective of this exploratory imaging study is to further characterize \[18F\]T807, an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker indicative of neurodegeneration in conditions such as AD).
Interventions
- DRUG [18F]T807
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02370524
The ClinicalTrials.gov registry entry for NCT02370524 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molecular NeuroImaging, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]T807 is the first listed.
NCT02370524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02370524 about?
NCT02370524 is a clinical study titled "Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease". The primary objective of this exploratory imaging study is to further characterize \[18F\]T807, an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker indicative of neurodegeneration in conditions such as AD).
What is the current status of trial NCT02370524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-01. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02370524?
The interventions under investigation include: [18F]T807 (DRUG).
Who is sponsoring clinical trial NCT02370524?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.